Overview

Update
IPO / Stock
Went Public on May 23, 2013 / NASDAQ:PTLA
Total Equity Funding
$249.1M in 5 Rounds from 21 Investors
Headquarters:
South San Francisco, CA
Description:
Portola Pharmaceuticals develops therapeutics for acute and chronic cardiovascular, and autoimmune and inflammatory diseases.
Founders:
,
Categories:
Biopharma, Therapeutics, Biotechnology
Website:
http://www.portola.com
Social:

Company Details

Update

Portola Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics for acute and chronic cardiovascular and autoimmune/inflammatory diseases. The company's products include PRT054021, an oral factor Xa inhibitor for the prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedic surgery; for stroke prevention in patients with atrial fibrillation; and for secondary prevention of myocardial infarction and stroke. Its products also include PRT060128, an oral and intravenous ADP receptor antagonist for the treatment of patients with acute coronary syndrome; for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention; and for secondary prevention of myocardial infarction and stroke. In addition, the company's products include PRT062607, an oral Syk-specific kinase inhibitor for treating chronic inflammatory diseases and Rheumatoid Arthritis (RA) which is used to treat certain cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Portola Pharmaceuticals, Inc. was founded in 2003 and is based in South San Francisco, California.

Funding Rounds (5) - $249.1M

Update
DateAmount / RoundValuationLead InvestorInvestors
Dec, 2011$9M / Private Equity0
Nov, 2011$89M / Series D2
Jun, 2009$60.1M / Series C17
May, 2007$70M / Series C12
Dec, 2003$21M / Series A5

Current Team (3)

Update

News (54)

Update
DateNews
Mar 24, 2016Houston Chronical - Portola Pharma and Williams skid, Office Depot and PVH climb
Feb 2, 2016PRNewswire UK All - Myelodysplastic Syndrome Market to Grow at 10% CAGR to 2019
Jan 18, 2016LifeSciVC | Recovering scientist turned early stage VC - Biotech’s Capital Intensity Challenge: A Post-Mortem on 2007’s Biggest Deals
Jan 18, 2016LifeSciVC | Recovering scientist turned early stage VC - Biotech IPO Returns: Great, Good, And Not So Good
Jan 18, 2016LifeSciVC | Recovering scientist turned early stage VC - Venture Debt: Under-Appreciated Tool for Building Biotechs
Dec 23, 2015Business Insider (tech) - New blood thinner 'antidote' to help doctors move past warfarin
Dec 3, 2015PRNewswire All - Mantle Cell Lymphoma Pipeline Research Report for H2 2015
Dec 3, 2015PRNewswire UK All - Mantle Cell Lymphoma Pipeline Research Report for H2 2015

Offices/Locations (1)

Update
  • Office

    270 E. Grand Avenue

    South San Francisco, CA 94080

    USA

Past Team (7)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Images

Add Videos